Regulation - Abilify, Otsuka

Filter

Current filters:

AbilifyOtsuka

Popular Filters

UK's NICE plans to recommend Abilify for children with bipolar disorder

10-06-2013

UK drugs watch dog the National Institute for Health and Care Excellence (NICE) has issued new draft…

AbilifyEuropeLundbeckNeurologicalOtsukaPharmaceuticalPricingRegulation

Otsuka files Abilify, first antipsychotic for major depressive disorder in Japan

04-09-2012

Japanese drugmaker Otsuka Pharmaceutical (TYO: 4768) has filed an additional indication for Abilify (aripiprazole)…

AbilifyAsia-PacificNeurologicalOtsukaPharmaceuticalRegulation

Additional indication for Otsuka’s Abilify in Japan

22-01-2012

Japanese drugmaker Otsuka Pharmaceutical (TYO: 4768) said last week that it has received new regulatory…

AbilifyAsia-PacificNeurologicalOtsukaPharmaceuticalRegulation

Company Spotlight

ImmunoGen

ImmunoGen

Back to top